Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sar-407899 Free Base. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 known ✓ | Q13464 | 12/20 | 0.72 |
| ▸ | ROCK2 known ✓ | O75116 | 3/20 | 0.55 |
| ▸ | IKBKB | O14920 | 2/20 | 0.58 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.55 |
| ▸ | PRKACA | P17612 | 1/20 | 0.55 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.55 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.55 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.55 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.55 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.55 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.55 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.55 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | CHUK | O15111 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | KHK | P50053 | 1/20 | 0.41 |
| ▸ | PRKX | P51817 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8148282 | 0.90 | ROCK1 (0.57) | ROCK1IKBKBROCK2PRKCDPRKACA | |
| SCHEMBL12211290 | 0.84 | ROCK1 (0.54) | ROCK1IKBKBROCK2PRKCDPRKACA | |
| SCHEMBL4007564 | 0.84 | ROCK1 (1.00) | ROCK1IKBKBROCK2PRKCDPRKACA | |
| SCHEMBL8934262 | 0.84 | ROCK1 (0.72) | ROCK1IKBKBROCK2PRKCDPRKACA | |
| Hydrochloric Acid SCHEMBL2500597 | 0.83 | ROCK1 (0.70) | ROCK1IKBKBROCK2PRKCDPRKACA | |
| SCHEMBL14981035 | 0.82 | ROCK1 (0.49) | ROCK1ROCK2KCNH2HRH3TDO2 | |
| SCHEMBL12192951 | 0.81 | ROCK1 (0.67) | ROCK1IKBKBROCK2PRKCDPRKACA | |
| SCHEMBL12192946 | 0.81 | ROCK1 (0.67) | ROCK1IKBKBROCK2PRKCDPRKACA | |
| Hydrochloric Acid SCHEMBL2503677 | 0.80 | ROCK1 (0.66) | ROCK1IKBKBROCK2PRKCDPRKACA | |
| SCHEMBL8939214 | 0.79 | ROCK1 (0.54) | ROCK1ROCK2KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-02 | — | — | US | disclosed |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-02 | — | — | US | disclosed |
| EP-1910333-B1 | PIPERIDINYL-SUBSTITUTED ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS | SANOFI SA (FR) | 2013-05-22 | — | — | EP | disclosed |
| US-8188117-B2 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| US-8188117-B2 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| EP-2385047-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI (FR) | 2011-11-09 | — | — | EP | disclosed |
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | disclosed |
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | disclosed |
| WO-2007012421-A1 | PIPERIDINYL-SUBSTITUTED ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS | SANOFI-AVENTIS (DE) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | MYLK2, MYLK, RHOT2 | ROCK1 8/4885ROCK2 10/4885IKBKB 606/4885 |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | ACE2, SARS1, ACE | ROCK1 3526/4885ROCK2 2665/4885IKBKB 2697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.